On Apr 11, 2017, A New Jersey federal judge entered a final judgment and injunction barring Actavis Inc., Roxane Laboratories Inc. and Alkem Laboratories Ltd. from releasing generic versions of Depomed Inc.’s opioid painkiller Nucynta (tapentadol) until related patents expire.

This final judgment is related to the opinion issued by New Jersey district court on Jan 13, 2017. In this opinion District court found that Alkem infringed all the three asserted patents (US patent nos. RE39593 expiring on Aug 5, 2022; 7994364 expiring on Jun 27, 2025 & 8536130 expiring on Sep 22, 2028) whereas Actavis & Roxane infringed 2 patents (US’593 & US’364). Also defendants have failed to prove by clear & convincing standard that these 3 patents are invalid.